[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment].
METHODS
A 66-year-old patient presented to our clinic with extensive left arm and left flank haematomas, anaemia, a prolonged activated partial thromboplastin time (aPTT), and reduced factor IX activity 6 weeks after prosthetic mechanical aortic valve implantation.


METHODS
Treatment with both vitamin K and a single injection of factor IX concentrate led to normalization of the activated partial thromboplastin time and factor IX activity, which remained constant for several days. No acquired factor IX inhibitor was detectable. Analysis of exon 2 of the factor IX gene revealed a C-->T mutation in codon 10 of the propeptide region, resulting in the substitution of alanine by valine. Echocardiography revealed a significant paravalvular leak.


METHODS
The substitution of valine for alanine in the factor IX propeptide leads to an impaired affinity of factor IX to the vitamin K-carboxylase complex. In this situation, treatment with coumarin derivatives can profoundly reduce factor IX activity and result in severe bleeding episodes. This patient was re-exposed to warfarin under close hematological monitoring. After 4 days factor IX activity had decreased to 15%, which was associated with an increase of the aPTT and a mild decrease of the prothrombin time. Due to rapid progression of the paravalvular leak and almost impossible long-term orale anticoagulation with coumarin derivatives, we recommended replacement of the prosthetic mechanical valve with a biological device.


CONCLUSIONS
The development of severe bleeding in the context of initiating warfarin therapy raises the suspicion of a factor IX propeptide mutation. The initial screening test is the activated partial thromboplastin time, which is elevated in the presence of the mutation. If concomitantly diminished factor IX activity is found the factor IX propeptide mutation should be excluded. Use of lifelong coumarin derivatives is contraindicated in patients with this mutation. However, a general screening of the activated partial thromboplastin time after coumarin initiation is not justified by cost/benefit analysis.
Neuhaus
T
T
Medizinische Universitäts-Poliklinik Bonn.
Hertfelder
H J
HJ
Hess
L
L
Oldenburg
J
J
Walger
P
P
Vetter
H
H
D000368:Aged; D000409:Alanine; D000925:Anticoagulants / Q000009:adverse effects*; D001021:Aortic Valve; D004452:Echocardiography; D005164:Factor IX / Q000008:administration & dosage / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D006350:Heart Valve Prosthesis; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D010314:Partial Thromboplastin Time; D010644:Phenprocoumon / Q000009:adverse effects*; D017354:Point Mutation; D011498:Protein Precursors / Q000235:genetics*; D014633:Valine; D014812:Vitamin K / Q000627:therapeutic use
D000925:Anticoagulants; D011498:Protein Precursors; C049838:factor IX Cambridge; D014812:Vitamin K; D005164:Factor IX; D014633:Valine; D000409:Alanine; D010644:Phenprocoumon